Tonix Pharmaceuticals has showcased encouraging preclinical data for its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025. The research highlights the vaccine's potential to provide comprehensive protection against mpox and rabbitpox, with significant implications for global public health.
The preclinical study revealed that TNX-801, a minimally replicative live-virus vaccine, demonstrated durable protection lasting six months. Notably, the vaccine showed efficacy across various test subjects, including immunocompromised animals, which represents a critical advancement in vaccine development.
The vaccine's characteristics align with the World Health Organization's preferred target profile for mpox vaccines. This alignment suggests TNX-801 could be a valuable tool in addressing current and potential future mpox outbreaks that have been declared global health emergencies.
The research comes at a crucial time when infectious disease prevention remains a global priority. By developing a single-dose vaccine with long-lasting protection, Tonix Pharmaceuticals is contributing to potential solutions for managing widespread viral threats.
The preclinical data presents a promising step toward developing a robust vaccine strategy for mpox, potentially offering a more accessible and effective approach to controlling the virus's spread across diverse populations.
